Kornimate/medical-research-clean huggingface dataset:
effect of 5% aqueous propolis in salivary and dental plaque ph in children

Conditions: Child; Saliva; Dental Plaque

Summary: this study aims to investigate the changes in saliva and dental plaque ph after consuming sugar-free chewing gum containing 5% of aqueous propolis in children aged between 8-11 years. the studied sample will be divided into two groups: group a (control group) placebo chewing gum, and group b (experimental group) aqueous propolis chewing gum. all children will experience both types of chewing gum with an interval of 1 week between the two studied groups.

this study will evaluate saliva and dental plaque ph after consuming 10% sucrose solution and then each child will test each of the two types of gum (aqueous propolis 5% and placebo gum) so that the child himself is the control and tested sample together, according to the following order: * in the first visit: the ph of saliva and dental plaque will be measured (before giving the sucrose solution, while chewing one of the two types of gum, and after giving the sucrose solution). * in the second visit: after a week, the ph of saliva and dental plaque will be measured (before giving the sucrose solution, while chewing the other types of gum, and after giving the sucrose solution).)

Eligibility criteria:
inclusion criteria: 1. children have mixed occlusion. 2. integrity of the buccal surfaces of the reference teeth (16, 21, 26, 36, 41, 46) from caries and developmental disorders 3. children with dmfs ≥5 according to who guidelines and standards. exclusion criteria: 1. systematic or mental disorders 2. medications that may affect the salivary flow rate or composition. 3. allergy to natural sugar substitutes. 4. children who wear fixed or removable orthodontic appliances. 5. children who have the habit of daily use of sugar substitute products.

Keywords: aqueous propolis chewing gum
metabolomic biomarkers evaluation in pulmonary fibrosis

Conditions: Pulmonary Fibrosis

Summary: pulmonary fibrosis (pf) are a heterogeneous group of interstitial lung diseases who may have a progressive phenotype often associated with loss of lung function, chronic respiratory symptoms, quality of life limitation as well significant morbidity and mortality. the identification of reliable biomarkers able to help in early diagnosis and predict disease progression are crucial for improving patient life. although many biomarkers have been proposed, there is no consensus on reliable markers for ipf. alterations in fatty acid (fa) metabolism have drawn increasing attention in the ipf pathogenesis, but there is no consensus on the specific fa changes. alterations in fa composition have been shown to promote pro-fibrotic traits in epithelial cells, fibroblasts, and myofibroblasts. however, while specific fatty acid (fa) alterations have been identified in the serum of ipf patients, no consensus exists on the exact changes for individual fas


Eligibility criteria:
inclusion criteria: * confirmed ipf diagnosis based on the 2018 ats/ers/jrs/alat guidelines \[pmid: 30168753\] or other fibrotising ilds within the past five years, * age ≥ 40 years, 3) ability to provide informed consent. exclusion criteria: * a current diagnosis of asthma or chronic obstructive pulmonary disease (copd), 2) an acute pf exacerbation within the past three months. * use of medications who may alter metabolomic biomarkers, ex. statins.

Keywords: metabolomic pulmonary fibrosis
the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate after transurethral resection of hunner lesion in interstitial cystitis/bladder pain syndrome patients

Conditions: Interstitial Cystitis

Summary: the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate after transurethral resection of hunner lesion in interstitial cystitis/bladder pain syndrome patients. to analyze the number and timing of recurrence based on a long-term follow-up.


Eligibility criteria:
inclusion criteria: 1. male and female aged 20 yrs or greater 2. patients diagnosed with hunner lesion in ic(interstitial cystitis)/bps(bladder pain syndrome) and who is scheduled to undergo transurethral resection 3. symptom persisted more than 6 months 4. pain vas ≥4 exclusion criteria: 1. history of augmentation cystoplasty or previous transurethral coagulation/resection due to ic/bps 2. child-bearing potential, pregnant or nursing women. 3. hematuria exceeds 1+ in the urinary dipstick (dipstick) examination. 4. urinary tract infection during run-in periods. 5. genitourinary tuberculosis or bladder,urethral and prostate cancer 6. recurrent urinary tract infection 7. history of hysterectomy,mid-urethral sling,pelvic organ prolapse repair,vaginal delivery or cesarean section,prostate operation or treatment etc within 6months. 8. neurologic disease history of cerebral infarction,multiple sclerosis or parkinsonism etc.- 9. using a indwelling catheter or execution of intermittent self catheterization
comparison of intra-operative radiotherapy with post-operative radiotherapy for women with ductal carcinoma in situ

Conditions: Breast Neoplasms

Summary: radiation therapy uses high-energy x-rays to damage tumor cells. giving radiation during surgery followed by external-beam radiation to the entire breast may kill more tumor cells.the clinical trial is conducting to compare the effectiveness of radiation therapy during surgery and whole-breast radiation therapy in treating women who have undergone breast-conversing surgery for intermediate or high grade ductal carcinoma in situ breast cancer.


Eligibility criteria:
inclusion criteria: * tumor diameter \< 5 cm * intermediate or high grade ductal carcinoma in situ * informed consent exclusion criteria: * no informed consent * tumor size \> 3,5 cm * low grade ductal carcinoma in situ * invasive carcinoma * no indication for a boost

Keywords: intermediate and high grade ductal carcinoma in situ （dcis）
intraprocedural determination of myocardial vitality using 2 different imaging methods

Conditions: Angina Pectoris; Left Ventricular Wall Motion Abnormalities

Summary: the investigators will compare myocard vitality diagnostics using 2d-strain echography and mri.

each patient with typical angina pectoris symptoms will get echocardiographic examination during the inclusion phase. if motion disorder of regional left ventricular myocardial wall is detected, patient will get coronary angiography (not study related, caused of typical angina pectoris symptoms and high probability of chd). if coronary stenosis related to motion disorder is available, patient will be randomized in two groups during coronary angiography. * first group: patient will get echocardiographic examination during coronary angiography. 2d-strain analysis will be performed based on data of this echocardiographic examination. only when vitality in the contraction impaired segments will be established based on 2d-strain analysis, pci (percutaneous coronary intervention) will be performed. * second group: coronary angiography by patient will be canceled. patients will get viability assessment using mri(magnetic resonance imaging) within the next 7 days. when vitality will be established with mri, patient will get pci (percutaneous coronary intervention). in addition, as part of a feasibility analysis, the possibility of a consolidation of data of coronary angiography with the ultrasound images will be researched by first group of patients. the aim is to simplify the visualization of the intraprocedural vitality detection. for this purpose, a position sensor based on electromagnetic fields (emt) will be used during coronary angiography.

Eligibility criteria:
inclusion criteria: * typical angina pectoris symptoms * echocardiographic determination of regional motion disfunction of left ventricular wall * establishment of needly treatment of stenosis related to motion disorder based on coronar angiography. * feasibility of mri-examination. * patients which are legally competent and which are mentally able to understand the study staff * patients give their written consent exclusion criteria: * allergy against contrast agent * patients with limited renal function(gfr \< 60 ml/min) * acute or instable angina pectoris

Keywords: coronary stenosis angina pectoris left ventricular wall motion abnormalities 2d-strain
study in adult patients with moderate to severe asthma

Conditions: Asthma

Summary: the cli-01535aa02-2 study is an exploratory study designed to compare two pressurised metered dose inhalers on subject's perception of asthma symptoms.

outpatients attending the hospital clinics/study centers will be recruited. moderate to severe asthma adult subjects will be recruited. a total of 75 subjects will be enrolled. the whole study will last approximately 6 weeks for each subject.

Eligibility criteria:
inclusion criteria: * subject's and/or subject legal representative's written informed consent obtained prior to any study related procedure. * age: ≥18 and ≤75 years of age. * established diagnosis of permanent asthma for at least 6 months prior to screening/randomisation visit * subject on maintenance therapy treated by foster® (chf1535 100/6 µg pmdi) for at least 6 months prior to screening/randomisation visit * asthma control test (act) ≥ 20 at screening/randomisation visit. * subject must have a cooperative attitude and the ability to be trained to use correctly the diary and answer the visual analogue scale (vas) * subject willing and able to download the application on their personal electronic device to fill in the study e-diary. * female subject of non-childbearing potential defined as physiologically incapable of becoming pregnant or female subject + male partner must be willing to use a highly effective birth control method from the signature of the informed consent and until visit 4 exclusion criteria: * pregnant or lactating woman * history of 'at risk' asthma * recent exacerbation * non-permanent asthma * asthma requiring more than 1 inhaler for maintenance treatment and more than 1 inhaler for reliever treatment. * asthma requiring use of biologics * respiratory disorders * lower tract respiratory infection * current smoker or ex-smoker with a smoking current use/history of ≥ 10 pack-years * cardiovascular diseases * subject with historical or current evidence of uncontrolled concurrent disease such as but not limited to hyperthyroidism, diabetes mellitus or other endocrine disease; haematological disease; autoimmune disorders * alcohol/drug abuse
alternate day versus daily oral iron therapy in adolescents

Conditions: Iron Deficiency Anemia; Heavy Menstrual Bleeding; Abnormal Uterine Bleeding

Summary: iron deficiency anemia affects over half of girls and young women with heavy periods and is the most common cause of anemia worldwide. most girls with heavy periods who also have iron deficiency anemia are prescribed iron to take by mouth every day by their doctor. there are some studies showing that taking iron every other day may actually help the iron be absorbed into the bloodstream better. this study is trying to compare how taking iron every other day compares to taking iron daily for treatment of anemia. the goal of this clinical research study is to learn which of the two methods of care will be the best way for girls and young women with iron deficiency anemia to take iron supplementation.

the research will be conducted at the following location(s): baylor college of medicine, tch: texas children's hospital, and tch: texas children's hospital clinic. if patient appears to qualify for the study they will sign and date this consent form, and the doctor will confirm that they are eligible for the study. the patient will complete the following procedures: * medical history including prior hospitalizations, lab results, medications, diet, social and family history * physical examination * blood samples: the patient will not have any extra blood draws (pokes) for this study. however, we will ask to take about 1/2 (0.5) teaspoons (3 ml) of extra blood for an extra research test when you have follow up blood test(s) in one month. patient will be on the study for 24 weeks (6 months),and will receive an information sheet about how to take iron to help it absorb in the stomach and on iron-rich foods. there are 2 different treatments in this study. if a patient enrolls, they cannot choose which treatment to receive. instead, they will be randomly assigned to one of the two treatments. that means there is a fifty percent chance they will receive iron medicine to take every day and a fifty percent chance they will receive iron medicine to take every other day.

Eligibility criteria:
inclusion criteria: 1. age 9 years or greater and less than age 22 years 2. heavy menstrual bleeding, defined as a pictorial blood assessment chart (pbac) score \>100 3. iron deficiency anemia, defined as both hemoglobin \<12 g/dl and ferritin \<15 ng/ml within 7 days of enrollment. exclusion criteria: 1. non-uterine cause of vaginal bleeding 2. pregnancy 3. chronic kidney disease 4. serology confirmed celiac disease 5. active gastrointestinal blood loss 6. active malignancy 7. inability to follow-up at texas children's hospital 8. receipt of intravenous iron within 30 days prior to enrollment 9. allergy or known inability to tolerate oral iron
drug utilization study on diane-35 (and generics) in three european healthcare databases

Conditions: Acne Vulgaris

Summary: the study objectives are to characterize new users of cyproterone acetate / ethinylestradiol (cpa/ee) in 2011/2012 and in 2014 according to demographics, treatment characteristics, previous diagnosis of acne, hirsutism or other hyperandrogenic conditions, previous acne treatment and (concomitant) use of hormonal contraceptives identified in healthcare databases in the uk (thin), the netherlands (pharmo) and italy (hsd).


Eligibility criteria:
inclusion criteria: * the study population will include all female patients registered in the investigated healthcare databases receiving cpa/ee in 2011 or 2012 (first run) or 2014 (second run), without a prescription of cpa/ee in the year prior to index date. only patients with recorded history in the database of ≥ 365 days prior to index date will be included in the study. exclusion criteria: * \<365 days recorded history in the database prior to index date * a prescription of cpa/ee in the year prior to index date
low-density lipoprotein cholesterol-targeting statin therapy versus the intensity-based statin therapy in patients with coronary artery disease

Conditions: Coronary Artery Diseasse

Summary: to compare clinical safety \& efficacy of fixed-high potent statin therapy (according to 2013 acc/aha guideline) vs. targeted ldl-c goal statin therapy (ldl\<70mg/dl) for secondary prevention. total 4400 patients with coronary artery disease patients requiring statin treatment were categorized fixed high-potent statin group and targeted ldl-c group. the investigators will compare primary endpoint (major adverse cardiac and cerebrovascular event (macce)) and secondary endpoint (1. new onset diabetes mellitus after randomization, 2. hospitalization due to heart failure, 3. deep vein thrombosis or pulmonary thromboembolism, 4. percutaneous trans-luminal angioplasty on peripheral artery obstructive disease, 5. aortic intervention or operation, 6. esrd with renal replacement therapy).


Eligibility criteria:
inclusion criteria: * patients ≥ 19 years old * patients clinically diagnosed with coronary artery disease including stable angina, unstable angina, acute non-st elevation myocardial infarction and acute st elevation myocardial infarction * patients with signed informed consent exclusion criteria: * pregnant women or women with potential childbearing * patients severe adverse events or hypersensitive to statin or patients with multi-drug allergy. * who had received drug that have a drug interaction with statin (strong inhibitor of cytochrome p-450 3a4 or 2c9) * patients with risk factors for myopathy with hereditary muscle disorder, hypothyroidism, alcohol use disorder, severe hepatic dysfunction (3 times normal reference values) or rhabdomyolysis * life expectancy \< 3 years * patient with who can not be followed up for more than 1 year * patients who cannot understand or read the consent form

Keywords: coronary artery disease ldl choelsterol statin
changes in serum antimüllerian hormone levels in patients 3 and 12 months after endometrioma sclerotherapy

Conditions: Endometriosis Ovary

Summary: endometriosis affects 6-10% of women in childbearing age. it is a heterogeneous disease with three different forms: superficial endometriosis (peritoneal), ovarian endometrioma and deep pelvic endometriosis (subperitoneal). surgical management of endometriomas is justified in cases of significant clinical symptoms (like pain), especially in cases of resistance to medical treatment. currently, laparoscopic cystectomy surgery is the recommended technique to treat ovarian endometrioma. however, it is now well demonstrated that this surgery significantly reduces the ovarian reserve. ethanol sclerotherapy is an alternative technique used to treat ovarian endometriomas. several studies demonstrated the effectiveness and safety of this treatment, particularly in terms of preserving fertility. regarding these reassuring data, many clinicians changed their practices and propose this technique as a first-line surgery. ovarian reserve comprises two elements: size of the primordial follicle stock and quality of the ovocytes. antimüllerian hormone (amh) has been shown to be the best marker of fertility. the aim of this study is to observe changes in amh levels after endometrioma sclerotherapy. this study is conducted in the hospices civils de lyon, in 3 different sites.


Eligibility criteria:
inclusion criteria: * patient in childbearing age from 18 to 42 years. * patient with uni- or bilateral endometrioma(s) without clinical and ultrasound criteria for ovarian carcinoma. * a sclerotherapy is programmed. * patient affiliated to a social security scheme. * patient who gave consent for this research. exclusion criteria: * doubt about the endometriotic origin of the cyst * suspect malignant ovarian disease. * pregnant or breastfeeding patient. * patient participating in other research with an exclusion period still in progress at the time of inclusion or those included in interventional research that interferes with the study protocol. * patient deprived of liberty by judicial or administrative decision. * patient (≥ 18 years old) under legal protection or unable to give consent. * patient does not speak french.

Keywords: endometrioma sclerotherapy ovarian reserve antimüllerian hormone
the expression of tlr2 and tlr4 in the lung of chronic obstructive pulmonary disease (copd) patients

Conditions: Smoking; COPD

Summary: smoking is the most important risk factor of copd, but only a fourth of smokers had copd in their life. there are also healthy smokers without evidence of copd. investigators hypothesize that innate immunity may affect this difference between copd patients and healthy smokers, because tlr4 is the receptor of lps, which is the one of important substance in cigarette. investigators will measure tlr2 and tlr4 expression in lung tissue of patients whose lung will be resected. investigators will compare the level of expression between copd patients and healthy smokers.


Eligibility criteria:
inclusion criteria: * all patients who will have lung resection for the therapeutic cause. exclusion criteria: * patients who do not agree with our study protocol
neoadjuvant stereotactic radiotherapy for brain metastasis

Conditions: Brain Metastases

Summary: this multicentre proof-of-concept study, involving 4 centers, aims to establish the value of fractionated neoadjuvant stereotactic radiotherapy (nasrt) as a new treatment paradigm for brain metastases (bm) in the frame of the czech neurooncology network. most relevant studies published to date used single-fraction radiotherapy and dealt with the inherent bias related to their retrospective nature. the researchers aim to increase the level of evidence for this treatment paradigm together with other similar ongoing studies.

the prospective study will evaluate the efficacy and toxicity of neoadjuvant stereotactic radiotherapy (nasrt) in patients with brain metastases (bm). clinical data gathered will include local control (lc), the incidence of leptomeningeal disease (lmd), radiological and clinical signs of radiation necrosis (rn), overall survival, and incidence of metachronous brain metastases. the magnetic resonance imaging (mri) characteristics of irradiated and subsequently resected bm will be obtained according to the usual protocol and specified time intervals. clinical monitoring will comprise neurological findings, karnofsky performance status, and quality of life (fact-br/eortc qlq-c30 questionnaire and eortc qlq-bn20 questionnaire. these questionnaires are designed to measure cancer patients' physical, psychological, and social functions. the questionnaires are composed of multi-item scales and single items). the data obtained from the retrospective control group (estimated for 160 patients) will include the same parameters monitored in the consecutive group of patients who underwent surgery at centers included in our study, with or without adjuvant radiotherapy (rt). formation of this control group corresponding to the nasrt group will enable the efficacy and risks of nasrt to be determined in comparison with established treatment modalities.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * karnofsky performance status ≥ 60 * histologically verified primary cancer disease * mri findings indicating bm * target bm indicated for surgical resection and any other metastases suitable for radical srt. * target bm between 1 cm and 7 cm at the longest diameter on t1 post-contrast mr imaging exclusion criteria: * confirmed hematological malignity * small-cell (lung) carcinoma * peracute condition requiring immediate neurosurgical intervention * history of whole-brain radiotherapy (wbrt) * history of stereotactic radiotherapy to a target brain metastasis * pregnancy * inability to perform surgical resection of the target bm within 7 days after nasrt

Keywords: brain metastases neoadjuvant stereotactic radiotherapy leptomeningeal disease quality of life overall survival acute toxicity
association between aldh2 gene polymorphism and atrial fibrillation

Conditions: Atrial Fibrillation

Summary: this study is a case-control study. in this study, 2ml of vein blood samples were collected from patients with atrial fibrillation undergoing radiofrequency ablation and those in the control group who underwent electrophysiological examination alone and confirmed no arrhythmia. the purpose of this study is to identify the relationship between the aldehyde dehydrogenase 2 (aldh2) gene polymorphism and susceptibility to atrial fibrillation, and to explore the relationship between the genotype of aldh2 snp and the prognosis of patients with atrial fibrillation undergoing radiofrequency ablation.


Eligibility criteria:
inclusion criteria: * signed informed consent; * age 18-85 years old, gender is not limited; ③ case group: patients with clinical diagnosis of atrial fibrillation who underwent radiofrequency ablation; control group: patients with no arrhythmia confirmed by electrophysiological examination; ④ able to communicate well with investigators and comply with the entire trial requirements. exclusion criteria: * those who cannot understand or refuse to sign the informed consent or follow-up; ②pregnant women, mentally retarded, mental/cognitive insufficiency and other possible vulnerable groups

Keywords: atrial fibrillation aldh2